Currently Viewing:
American Society of Hematology Annual Meeting & Exposition
Research to Look Out for at ASH 2018
November 26, 2018
Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings
December 01, 2018
Studies at ASH Evaluate Episodic ED Utilization, Adherence, QOL in Sickle Cell Disease
December 01, 2018
Dr Theresa Keegan: AYAs Continue to Be Underrepresented in Clinical Trials
December 01, 2018
Currently Reading
Dr Elizabeth Griffiths: Mutational Data Help Inform Clinical Prognosis, Treatment Protocol in AML
December 01, 2018
Dr Jeff Sharman Discusses Standard of Care for CLL Based on Treatment Setting
December 03, 2018
Dr Alison Moskowitz on the Importance of Patients Understanding Their Diagnosis, Treatment Options
December 03, 2018
Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL
December 03, 2018
ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection
December 03, 2018
iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL
December 03, 2018
Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome
December 03, 2018
Dr Robert Rifkin Outlines Recent Treatment Advances in Multiple Myeloma
December 03, 2018
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 18, 2018
Dr Jeff Sharman: Cost of Therapy Is a Major Challenge in CLL
January 06, 2019
Dr Theresa Keegan on Barriers, Facilitators to Clinical Trial Participation Among AYAs
January 07, 2019
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
January 08, 2019
Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple Myeloma
January 10, 2019
Dr Robert Rifkin on Lack of Education Surrounding Biosimilars
January 22, 2019

Dr Elizabeth Griffiths: Mutational Data Help Inform Clinical Prognosis, Treatment Protocol in AML

We’re beginning to understand that mutational profiles can tell us something about the character of the leukemia, said Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center.


We’re beginning to understand that mutational profiles can tell us something about the character of the leukemia, said Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center.

Transcript

How are mutational data helping inform clinical prognosis and treatment protocol?

I think we’re beginning to understand that mutational profiles can tell us something about the character of the leukemia. Historically, we define patients as either fit for induction or unfit, and we made therapy decision largely based on those clinical factors. Using mutational profiles, we can actually identify patients whose disease is likely to be intransigent to conventional chemotherapies, and with that approach, we can actually slate patients to receive therapies that are more likely to benefit them.

So, instead of giving them traditional cytotoxic therapies, which tend to have a very low rate of remission induction, in say patients with p53 mutant disease or complex kayrotype. We might offer them an alternative induction strategy, potentially with a novel therapeutic combination like one of the venetoclax combinations. I think that recognition is likely to change the way we approach patients in the future.

Right now, a fit patient would still likely be offered a conventional induction strategy or Vyxeos, the CPX-351 liposomal cytarabine-daunorubicin combination. But perhaps in the future, we might be able to change our approach.

I think the molecular profiling has also unveiled a variety of targets that we can use in combination with traditional chemotherapeutics. So, as highlighted at this meeting by Keith W. Pratz, MD, associate professor of oncology, John Hopkins University, and Eytan Stein, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, upfront combinations of both novel Flt-3 inhibitors and IDH [isocitrate dehydrogenase] inhibitors with conventional chemotherapy like 7+3 can provide really substantial rates of remission induction success and potentially deep molecular emissions, which may translate into better long-term survival for patients.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up